The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Results of the CARTITUDE-4 trial assessing patient-reported outcomes in those with multiple myeloma receiving the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel
The IRAK-4 inhibitor emavusertib showed encouraging clinical activity in patients with higher-risk myelodysplastic syndromes (MDS), according to preliminary data from the phase 1/2
The largest study to date evaluating the impact of circulating lymphoma cells (CL) on outcomes in patients with newly diagnosed de novo diffuse
he US Food and Drug Administration (FDA) has granted orphan drug designation for VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor for the
Dr. Jabbour discusses obecabtagene autoleucel (obe-cel), an autologous CD19-directed chimeric antigen receptor (CAR)-T cell therapy, in relapsed or refractory adult B-cell acute lymphoblastic
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for imetelstat in the treatment
I am so excited about this new format and tool by which [clinicians] can keep up to date in cancer discoveries and hear
The US Food and Drug Administration (FDA) has approved obecabtagene autoleucel (obe-cel) in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Dasatinib has shown efficacy in treating patients with Philadelphia chromosome-positive (Ph+) acute leukemia, though some patients develop resistance. The authors of a phase
